A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

(iMMersioN Trial)

Recruiting at115 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: argenx

No Placebo Group

Trial Summary

What is the purpose of this trial?

This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.

Research Team

Eligibility Criteria

Inclusion Criteria

You are able to provide written permission and meet the study requirements.

You have been diagnosed with MMN by a certified neurologist or neuromuscular specialist.

You are of legal age to consent to clinical studies as dictated by the local laws when signing the Informed Consent Form.

Treatment Details

Who Is Running the Clinical Trial?

argenx

Lead Sponsor

Trials

76

Recruited

11,500+

Tim Van Hauwermeiren

argenx

Chief Executive Officer since 2008

B.Sc. and M.Sc. in Bioengineering from Ghent University, Executive MBA from The Vlerick School of Management

Dr. Peter Ulrichts

argenx

Chief Medical Officer since 2023

MD from Maastricht University, PhD in Molecular Immunology from Maastricht University